Carprieve 100 mg Tablets for Dogs

Composition

Each tablet contains:

Active substance:

Carprofen 100 mg

Excipients:

Tablet.

A yellow circular tablet of 8 mm diameter, 100 embossed on one side and a single break-line on the other side.

The tablets can be divided into halves.

3

Pharmacological properties

4.1 ATCvet code:

QM01AE91

4.2 Pharmacodynamics

Carprofen, (±)-6-chloro-α-methylcarbazole-2-acetic acid, is a non-steroidal anti- inflammatory drug (NSAID). It is a derivative of phenylpropionic acid and a member of the arylpropionic acid class of NSAIDs. As a representative of the 2-arylpropionic family, it contains a chiral center at C2 of the propionic moiety and therefore, exists in 2 sterioismeric forms, the (+)-S and (-)-R enantiomers.

Carprofen possess anti-inflammatory, analgesic and anti-pyretic activity. Carprofen like most other NSAIDs is an inhibitor of the enzyme cyclo-oxygenase of the arachidonic acid cascade. However the inhibition of prostaglandin synthesis by carprofen is slight in relation to its anti-inflammatory and analgesic potency. The precise mode of action of carprofen is not clear.

4.3 Pharmacokinetics>

Absorption is rapid with >90% absorption after oral administration. The volume of distribution is small and carprofen is highly bound to plasma proteins.

Biotransformation of carprofen occurs in the liver to from the ester glucuronide and two 1-O-acyl-β-D-glucuronide diastereoisomers. These are secreted in the biliary tract and excreted in the faeces. The Cmax is 28.51 µg/ml and the AUC is 237.33 µg/ml.hr.

3

Target species

Dogs.

3

Indications

Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post operative pain.

3

Dosage

Oral use.

4 mg carprofen per kg bodyweight per day.

An initial dose of 4 mg carprofen per kg bodyweight per day given as a single dose or in two equally divided doses. The daily dose may be reduced, subject to clinical response.

Duration of treatment will be dependent upon the response seen. Long-term treatment should be under regular veterinary supervision.

Do not exceed the stated dose.

To extend analgesic and anti-inflammatory cover post-operatively parenteral pre- operative treatment with an injectable Carprofen product may be followed with the veterinary medicinal product at 4 mg/kg/day for up to 5 days.

Return any halved tablets to the original pack and use at the next administration. Any halved tablets remaining after the last administration of the product must be discarded.

3

Contraindications

Do not use in cats.

Do not use in pregnant or lactating bitches.

Do not use in puppies less than 4 months of age.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where three is evidence of a blood dyscrasia.

3

Adverse reactions

Target species: Dogs

Very rare (<1 animal / 10 000 animals treated, including isolated reports):

Renal disorder1 Hepatopathy1 Vomiting2 Diarrhoea2 Blood in faeces2 Appetite loss2 Lethargy2

1As with other NSAIDs, there is a risk of renal or idiosyncratic hepatic adverse events.

2Typical undesirable effects associated with NSAIDs that generally occur within the first week of treatment.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3

Warnings

Special precautions for safe use in the target species:

Use in aged dogs may involve additional risk.

If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

Avoid use in any dehydrated, hypoproteinemic, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity..

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion, seek medical advice immediately and show package leaflet or label to the physician.

Wash hands after handling the veterinary medicinal product.

Special precautions for the protection of the environment:

Not applicable.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3

Use during pregnancy, lactation or lay

Pregnancy and lactation:

Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.

3

Interactions

Do not administer other NSAIDs and glucocorticoids concurrently or within 24 hours or each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.

Concurrent administration of potential nephrotoxic drugs should be avoided.

3

Overdose

Do not exceed the stated dose. There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.

3

Special warnings

None.

3

Withdrawal period

Not applicable.

3

Incompatibilities

Not applicable.

3

Immediate packaging

The veterinary medicinal product are supplied in either:

Polypropylene Snap Secure Tubs containing 14, 30 or 100 tablets, sealed with a white low density Polyethylene Snap Secure Cap, or Aluminium-Aluminium blister strips of 10 tablets in cartons containing 10, 20, 30, 50, 60, 70, 100, 140, 180, 200, 250, 280, 300, 500 or 1000 tablets.

Not all pack sizes may be marketed.

3

Storage

Do not store above 25°C.

Protect from light.

Store in a dry place.

3

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

3

Disposal of unused product

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

3

Additional information

Vm 02000/4283

8 DATE OF FIRST AUTHORISATION

21 July 2009

9 DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

April 2026

10 CLASSIFICATION OF VETERINARY MEDICINAL PRODUCT

Veterinary medicinal product subject to prescription.

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

Approved 12 May 2026

3

Registration holder

Norbrook Laboratories Limited

3